In this light, downregulation of some TAS2R, as observed in subgroups of patients, in particular in TP53- and TET2-mutated, might be a strategy adopted by AML cells to evade possible growth-suppressive effects, as demonstrated in breast cancer cells (18). This evidence concerns the gene TP53 and acute myeloid leukemia.